NORTH CHICAGO, Ill., July 10, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 8, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,373,039 shares of common stock with a par value of $0.01

MISGAV, Israel and MONHEIM, Germany, July 10, 2019 /PRNewswire/ -- The Bayer Trendlines Ag Innovation Fund, set up by Bayer CropScience LLC ("Bayer") and The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced that it established EcoPhage Ltd. ("EcoPhage"), a new company focused on discovering an

VANCOUVER, British Columbia and MENLO PARK, Calif., July 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar

CLEVELAND, July 10, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® System is the focus of more than 40 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2019 Annual Meeting. AAPM is the largest association of medical physicists in the world, and this year's

UPPSALA, Sweden, July 10, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has signed an agreement granting Mundipharma Pty Limited (Mundipharma Australia) the exclusive rights to commercialize Orexo's lead product, Zubsolv®, for the treatment of opioid depen

DUBLIN, July 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement under which Jazz has acquired Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors.  Redx will perform certain pre-clinical activities for the program under a separate coll

SUZHOU, China, July 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed in China with avapritinib in the ongoing global Phase III VOYAGER clinical trial. This study is designed to evaluate the safety and efficacy of avapritinib as a third-line or fourth-line treatment

NEW YORK, July 9, 2019 /PRNewswire/ -- A cyber vulnerability has been discovered in hospital anesthesia machines, the US Department of Homeland Security's Industrial Control Systems – Cyber Emergency Response Team (ICS-CERT) disclosed today. The vulnerability, discovered by healthcare cybersecurity provider CyberMDX, could allow an attacker to impair res

WASHINGTON, July 9, 2019 /PRNewswire/ -- The U.S. Agency for International Development Office of Inspector General, or USAID OIG, hosted its third annual oversight roundtable for international development and humanitarian aid implementers. This year's event centered on preventing sexual exploitation and abuse in foreign assistance programs, with participants fr

DENVER, July 9, 2019 /PRNewswire/ -- DaVita Kidney Care is energized by the focus from the Administration on kidney health. These government i